{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:27:29Z","timestamp":1793600849144,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijcard.2026.134466","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:45:53Z","timestamp":1774583153000},"page":"134466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Incidence and outcomes of atrial arrhythmia with cyclin dependent kinase 4\/6 inhibitors in hormone receptor-positive \/ human epidermal growth factor receptor 2-negative breast cancer"],"prefix":"10.1016","volume":"454","author":[{"given":"Nathaniel E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134466_bb0005","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with Ribociclib plus Letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134466_bb0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0015","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with Palbociclib and Fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134466_bb0020","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134466_bb0025","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2026.134466_bb0030","first-page":"12","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","author":"Fradley","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134466_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e13038","article-title":"Cardiac complications of CDK4\/6 inhibitors for breast cancer","volume":"38","author":"Master","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaccao.2021.01.009","article-title":"Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability","volume":"3","author":"Ye","year":"2021","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162869","article-title":"Profiling the cardiovascular toxicities of CDK4\/6 inhibitors: a real-world pharmacovigilance study","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijcard.2026.134466_bb0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FJC.0000000000001182","article-title":"Atrial fibrillation induced by anticancer drugs and underling mechanisms","volume":"80","author":"Burashnikov","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11838","article-title":"Association of early-stage breast cancer and subsequent chemotherapy with risk of atrial fibrillation","volume":"2","author":"Abdel-Qadir","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ijcard.2026.134466_bb0065","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-medicare analysis","volume":"43","author":"Guha","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134466_bb0070","first-page":"11","article-title":"Breast cancer and atrial fibrillation","author":"Mauro","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijcard.2026.134466_bb0075","article-title":"Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study","author":"Chen","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134466_bb0080","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2026.134466_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011006","article-title":"Systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of Interleukin-6-mediated changes in Connexin expression","volume":"8","author":"Lazzerini","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134466_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41569-022-00759-w","article-title":"Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology","volume":"20","author":"Dobrev","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134466_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035710","article-title":"Assessment of inflammatory biomarkers and incident atrial fibrillation in older adults","volume":"13","author":"Shitole","year":"2024","journal-title":"J. Am. Heart Assoc."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326003153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326003153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:37:58Z","timestamp":1793597878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326003153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S0167527326003153"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134466","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and outcomes of atrial arrhythmia with cyclin dependent kinase 4\/6 inhibitors in hormone receptor-positive \/ human epidermal growth factor receptor 2-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134466"}}